Navigation Links
Molecule plays early role in nonsmoking lung cancer
Date:7/27/2009

COLUMBUS, Ohio The cause of lung cancer in never-smokers is poorly understood, but a study led by investigators at the Ohio State University Comprehensive Cancer Center and at the National Cancer Institute has identified a molecule believed to play an early and important role in its development.

The findings, published online recently in the Proceedings of the National Academy of Sciences, may lead to improved therapy for lung cancer in both never-smokers and smokers, including those with tumors resistant to targeted drugs such as gefitinib.

The study examined lung tumors from people who had never smoked and found high levels of a molecule called miR-21. The levels were even higher in tumors that had mutations in a gene called EGFR, a common feature of lung cancer in never-smokers.

"Several important lung cancer drugs target EGFR mutations, but these agents are ineffective in about 30 percent of cases in which the mutation is present," says co-principal investigator Dr. Carlo M. Croce, professor of molecular virology, immunology and medical genetics at the Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute. "Our study suggests that developing agents to inhibit miR-21 might improve these anti-EGFR therapies."

About 15 percent of the 219,000 lung cancer cases expected this year in the United States 32,850 people will occur in individuals who have never smoked.

Croce and his colleagues began their study by comparing 28 cases of lung tumor tissue and nearby healthy lung tissue from never-smokers for changes in microRNA, molecules that help cells regulate the kind and amount of proteins they make.

The cancer cells showed abnormally elevated levels of five microRNAs, with miR-21 increased two and a third times, the highest of all. An earlier study of smoking-related lung cancer by the same investigators also showed elevated levels of that molecule.

Furthermore, the molecule was equally high in early stage tumors and late stage tumors, suggesting that this change happens early in lung cancer development, says Croce, who also directs Ohio State's Human Cancer Genetics program.

Using lung cancer cell lines, the investigators learned that EGFR regulates miR-21. For example, altering EGFR levels caused corresponding changes in miR-21.

Last, the investigators took cells that had a mutated EGFR gene and treated them with an anti-EGFR agent (the agent was related to gefitinib and erlotinib, targeted drugs used to treat lung cancers with EGFR mutations). As expected, many of the cells died. But when they blocked both EGFR and miR-21, the proportion of cells killed rose still more.

Overall, Croce says, "Our study suggests that the combined use of an EGFR inhibitor and a miR-21 inhibitor might improve therapy for many cases of lung cancer, and rescue lung cancer cases that have acquired resistance to several targeted drugs."


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. Molecule Helps Leukemia Cells Hide From Immune System
2. Small Molecule Might Play Big Part in Lung Cancer
3. New role discovered for molecule important in development of the pancreas
4. Fate Therapeutics to Present Data on Stimulation of Osteogenic Activity Using Small Molecule Modulators of Wnt Pathway
5. Ready for relapse: Molecule helps breast cancer cells to survive in the bone marrow
6. LSUHSC research identifies enzyme that makes survival molecule for key vision cells
7. Ludwig Institute of Cancer Research Ltd., Brussels Branch, Issues Statement Concerning Prospect Therapeutics Incs. GCS-100 Molecule
8. Small molecule inhibitor shows promise in trastuzumab-resistant metastatic breast cancer
9. Molecule in Skin May Link Eczema and Asthma
10. Molecule prompts damaged heart cells to repair themselves after a heart attack
11. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-101, Potent Small Molecule for Treatment of Alzheimers Disease.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... 23, 2017 , ... PM360, the premier information resource for ... winners of its 3rd Annual ELITE Awards. The ELITE (Exceptional • Leaders • ... industry today. , Out of more than 500 submissions, 100 winners were selected ...
(Date:5/23/2017)... ... May 23, 2017 , ... New England Journal Of Medicine Confirms ... a Policy Response”, -The Rory Staunton Foundation Calls on Health & Human Services, Tom ... of Sepsis ( http://www.rorystauntonfoundation.org ) today reported on a new study released on May ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... ... certification body for exercise professionals, is pleased to announce the organization’s Certified Strength ... , The NCSF Certified Strength Coach (CSC) program validates the competency of qualified ...
(Date:5/23/2017)... Newport Beach, CA (PRWEB) , ... May 23, ... ... Board Certified Facial Plastic and Reconstructive Surgeon Dr. Kevin Sadati, is pleased to ... patients interested in building collagen and elastin in their face, neck, and body ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... educating patients on peri-implantitis in Las Vegas, NV, and the importance ... custom gum disease consultation and leading care for peri-implantitis, with or without a ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... has earned a spot on Forbes, "America,s ... ranked among 500 U.S. employers as well as in ... Services. The annual Forbes rankings ... of over 30,000 employees across 25 industries. The survey ...
(Date:5/8/2017)... , May 8, 2017 MACRA ... transition from fee for service reimbursement. Black Book Research ... 1.       The Market for MIPS Compliance ... 77% of physician practices with 3 or more clinicians ... Solutions by Q4. "Given the magnitude of the changes, ...
(Date:5/6/2017)... , May 5, 2017  Hill-Rom Holdings, Inc. ... add approximately 100,000 square feet to its Welch Allyn ... 2016 its commitment to bring more than 100 new ... where Welch Allyn has maintained a significant presence for ... accommodate these new positions, a large portion of which ...
Breaking Medicine Technology: